Monaco Asset Management SAM Has $11.25 Million Stake in Maravai LifeSciences Holdings, Inc. $MRVI

Monaco Asset Management SAM trimmed its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 5.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,460,190 shares of the company’s stock after selling 196,147 shares during the period. Maravai LifeSciences accounts for about 1.9% of Monaco Asset Management SAM’s portfolio, making the stock its 11th biggest holding. Monaco Asset Management SAM owned approximately 1.35% of Maravai LifeSciences worth $11,246,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in MRVI. Jane Street Group LLC increased its stake in shares of Maravai LifeSciences by 1,463.1% during the first quarter. Jane Street Group LLC now owns 380,403 shares of the company’s stock worth $841,000 after purchasing an additional 356,067 shares during the period. Creative Planning increased its stake in shares of Maravai LifeSciences by 49.6% during the second quarter. Creative Planning now owns 116,031 shares of the company’s stock worth $280,000 after purchasing an additional 38,450 shares during the period. Rhumbline Advisers increased its stake in shares of Maravai LifeSciences by 20.3% during the second quarter. Rhumbline Advisers now owns 195,272 shares of the company’s stock worth $471,000 after purchasing an additional 32,940 shares during the period. Prudential Financial Inc. bought a new position in shares of Maravai LifeSciences during the second quarter worth approximately $36,000. Finally, Invesco Ltd. increased its stake in shares of Maravai LifeSciences by 16.8% during the second quarter. Invesco Ltd. now owns 282,192 shares of the company’s stock worth $680,000 after purchasing an additional 40,495 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.

Maravai LifeSciences Price Performance

Maravai LifeSciences stock opened at $4.80 on Monday. The stock’s fifty day moving average price is $3.66 and its two-hundred day moving average price is $3.54. Maravai LifeSciences Holdings, Inc. has a one year low of $1.99 and a one year high of $4.99. The company has a debt-to-equity ratio of 0.72, a current ratio of 5.91 and a quick ratio of 4.96. The firm has a market cap of $1.24 billion, a PE ratio of -6.76 and a beta of 0.71.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The firm had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. As a group, research analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MRVI has been the topic of a number of recent research reports. Weiss Ratings upgraded Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Wells Fargo & Company increased their target price on Maravai LifeSciences from $4.50 to $5.50 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Wall Street Zen upgraded Maravai LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a research note on Friday, May 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.